Alzheimer’s vaccine

Axon Neuroscience , has reported successful Phase I clinical trial of a vaccine named AADvacI, against the “tau” protein, that  cause the neurodegenerative disorders associated with Alzheimer’s disease. AADvac I stimulates body’s immune system to produce specific antibodies against defective tau protein and protects the brain from degeneration.